Senovia Biosciences is pioneering Metabolic Therapeutics, a transformative new class of medicines designed to address unmet needs in rare, neurodegenerative, and metabolic diseases.

Our approach redefines how we treat complex conditions—opening a new frontier in human health.

Learn more about our pipeline

  • Drives −22 % body-weight drop and −50 % fat mass via higher energy expenditure while fully preserving lean mass.

  • Huma proof of concept data:

    27/27 improved

    44% hit CGI‑S=1

    PANSS 91.4→49.3 (−42); CGI‑S −2.9 (d≈3.8)

    100% of adherent patients cleared metabolic syndrome; visceral fat −36%.

  • Proof of concept class data:

    +574% seizure‑free latency (oxygen‑tox model)

    Angelman: ~50% fewer seizures + memory rescue

    Dravet: +24% latency & ~5× fewer seizure deaths

    Kv1.1−/−: ~50% drop in spontaneous seizures

    PTZ: +15% threshold; +60% extra cut with levetiracetam (add‑on).

  • Cuts Aβ / p-Tau ~50 % and restores memory to near-wild-type in 3×Tg-AD mice; rescues 95 % viability in human iPSC-AD neurons.

  • SNV-401 is a first-in-class oral therapy candidate for cancer cachexia that preserves muscle function and extends survival.
    Preclinical: +103% survival as an adjunct metabolic therapy (VM-M3), full preservation of muscle force, and ~47% fewer lung metastases.